Completed OBSERVATIONAL NCT00802178

First Presentation of Parkinson Disease Patients to Neurologist

CEE PMSS (Central Eastern European Post-Marketing Surveillance Study) First Presentation of Mirapexin in Parkinson Patients

Sponsor: Boehringer Ingelheim

Conditions Parkinson Disease

Updated 7 times since 2017 Last updated: Mar 14, 2014 Started: Feb 28, 2006 Primary completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00802178, this observational or N/A phase trial focuses on Parkinson Disease and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alba Iulia, Romania , Arad, Romania , Arandjelovac, Serbia , Bacau, Romania , Baia Mare, Romania , Balassagyarmat, Hungary , Banská Bystrica, Slovakia , Belgrade, Serbia , Berettyóújfalu, Hungary , Bistriţa, Romania and 168 more locations